# A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Source: https://onco.cc/trials/nct05980481/  
OnCo record `nct05980481` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Trastuzumab, Toripalimab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., active and no longer recruiting.

## Summary

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer is a phase 2/3 interventional study registered as NCT05980481 by RemeGen Co., Ltd., with 201 participants enrolled, started 2023-08-04 and due to reach its primary completion in 2025-07-10. Interventions recorded: RC48-ADC（2.5mg/kg）, Trastuzumab, Toripalimab, Oxaliplatin（130mg/m2 ）, Capecitabine（1000mg/m2） and RC48-ADC（2.0mg/kg）.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05980481
- Phase: 2/3
- Setting: A Study of RC48-ADC Combine With Toripalimab and Chemotherapy or RC48-ADC Combine With Toripalimab and Trastuzumab as First-line Treatment in Local Advanced or Metastatic Gastric Cancer With the HER2 Expression or Non-expression
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 201

## Sources

- ClinicalTrials.gov NCT05980481: https://clinicaltrials.gov/study/NCT05980481

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Toripalimab](https://onco.cc/drugs/toripalimab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct05980481.json